National Institute for Health Research: Promising Motor Neurone Disease Drug Helps Slow Disease Progression
September 23, 2022
September 23, 2022
LONDON, England, Sept. 23 (TNSjou) -- The National Institute for Health Research issued the following news:
A landmark trial supported by NIHR researchers has found an experimental drug targeting a rare form of motor neurone disease showed significant physical benefits after 12 months.
The phase 3 clinical trial, published in the New England Journal of Medicine, has shown that the new investigational drug tofersen can slow and reduce progression of the disease in patie . . .
A landmark trial supported by NIHR researchers has found an experimental drug targeting a rare form of motor neurone disease showed significant physical benefits after 12 months.
The phase 3 clinical trial, published in the New England Journal of Medicine, has shown that the new investigational drug tofersen can slow and reduce progression of the disease in patie . . .